Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Jazz Pharmaceuticals Research UK Limited has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 8 examiners and 7 art units, and BAGNAL, CINDY LILIANA is the busiest examiner with 1 pending action.
Each action has a distinct examiner, while one art unit handles more than one matter. The profile supports centralized portfolio oversight for recurring technical themes, combined with application-specific responses. Examiner-level precedent is unlikely to transfer broadly across the docket.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAGNAL, CINDY LILIANA | 1 | — | — |
| MCKOY, QUINCY ANDRE | 1 | 68.4% | +39.8% |
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| MATTISON, LORI K | 1 | 15.2% | +27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786949 | ORAL CANNABINOID FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 22d overdue |
| 18560316 | 6-HYDROXY-CANNABIDIOL-C4 | HAVLIN, ROBERT H | 8d overdue |
| 18546254 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | BAUER, BRIANNA LEE | 20d |
| 18912442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | MCKOY, QUINCY ANDRE | — |
| 18560337 | DERIVATIVES OF CANNABIDIOL-C4 FOR THE TREATMENT OF EPILEPSY | FOWLER, ALAN JEROME | — |
| 15640033 | CANNABINOID FORMULATIONS | MATTISON, LORI K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | CHANG, KYUNG SOOK | 43d overdue |
| 17786949 | ORAL CANNABINOID FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 22d overdue |
| 18560316 | 6-HYDROXY-CANNABIDIOL-C4 | HAVLIN, ROBERT H | 8d overdue |
| 18912442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | MCKOY, QUINCY ANDRE | — |
| 15640033 | CANNABINOID FORMULATIONS | MATTISON, LORI K | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1621 | 1 |
| 1613 | 1 |
| 1691 | 1 |
| 1623 | 1 |
| 1622 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18874175 | CRYSTALINE FORMS OF A SYNTHETIC CANNABINOID | BAGNAL, CINDY LILIANA | 1621 | §112 | Non-Final OA | — | Pending | Dec 12, 2024 |
| 18912442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | MCKOY, QUINCY ANDRE | 1626 | §103§112 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | CHANG, KYUNG SOOK | 1613 | §103DP | Final Rejection | 43d overdue | Pending | Mar 06, 2024 |
| 18560337 | DERIVATIVES OF CANNABIDIOL-C4 FOR THE TREATMENT OF EPILEPSY | FOWLER, ALAN JEROME | 1691 | §102§103 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18560316 | 6-HYDROXY-CANNABIDIOL-C4 | HAVLIN, ROBERT H | 1626 | §101§102§103Other | Final Rejection | 8d overdue | Pending | Nov 10, 2023 |
| 18546254 | USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY | BAUER, BRIANNA LEE | 1623 | §102§103§112Other | Non-Final OA | 20d | Pending | Aug 11, 2023 |
| 17786949 | ORAL CANNABINOID FORMULATIONS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §101§103Other | Final Rejection | 22d overdue | Pending | Jun 17, 2022 |
| 15640033 | CANNABINOID FORMULATIONS | MATTISON, LORI K | 1619 | §103§112DP | Non-Final OA | — | Pending | Jun 30, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJazz Pharmaceuticals Research UK Limited has 8 pending office actions as of October 2026, spread across 7 art units and 8 examiners.
Cindy Liliana Bagnal has the most, with 1 of Jazz Pharmaceuticals Research UK Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
